Esperion Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2011 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Esperion Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2011 to 2023.
  • Esperion Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$16M, a 41.8% increase year-over-year.
  • Esperion Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $16.5M.
  • Esperion Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$156M, a 13.3% increase from 2022.
  • Esperion Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$180M, a 20.8% increase from 2021.
  • Esperion Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$227M, a 86.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.